Latest news and press releases about Lineage Cell Therapeutics, Inc. (LCTX): earnings reports, analyst upgrades/downgrades, product launches, partnerships and regulatory filings. Stay updated on every market-moving event.
Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, developing cell replacement therapies to treat serious medical conditions in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the age-related macular degeneration; and OPC1, an allogeneic oligodendrocyte progenitor cell therapy that is in Phase 1/2a multicenter c...
Price
| Price | $1.07 |
| Market Cap | $267M |
| Exchange | AMEX |
| Country | US |
Valuation Ratios
| Price / Book | 4.42 |
| EV / EBITDA | -6.05 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | -71.14% |
| Return on Invested Capital | -23.25% |
| Return on Assets | -30.37% |
| Gross Margin | 96.59% |
| Operating Margin | -205.23% |
| Net Margin | -246.58% |
Related companies: ADCT · AUTL · BNTC · FULC · GALT · NGNE · OCGN
Explore sector: Healthcare · Biotechnology
More sections of LCTX: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks